Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Adagene Inc

Healthcare US ADAG

3.98USD
0.14(3.65%)

Last update at 2026-06-23T20:00:00Z

Day Range

3.504.07
LowHigh

52 Week Range

1.304.75
LowHigh

Fundamentals

  • Previous Close 3.84
  • Market Cap251.08M
  • Volume187523
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-20.99943M
  • Revenue TTM7.67M
  • Revenue Per Share TTM0.16
  • Gross Profit TTM 7.67M
  • Diluted EPS TTM-0.38

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -17.90727M -33.44166M -17.25496M -79.51279M -71.47632M
Minority interest - - - - -
Net income -17.60941M -33.42411M -18.94637M -79.97185M -73.17794M
Selling general administrative 7.08M 7.27M 8.67M 11.87M 14.44M
Selling and marketing expenses - - 0.01M - -
Gross profit 7.67M -0.82304M 18.11M 9.29M 10.18M
Reconciled depreciation 0.59M 0.94M 1.21M 1.45M 1.13M
Ebit -21.49499M -32.58979M -16.15924M -83.92068M -72.36409M
Ebitda -20.91236M -31.66354M -14.95078M -81.37479M -70.50910M
Depreciation and amortization 0.58M 0.93M 1.21M 2.55M 1.85M
Non operating income net other - - - - -
Operating income -21.43830M -35.95154M -23.71987M -83.92068M -72.36409M
Other operating expenses 29.11M 36.05M 41.83M 93.21M 82.54M
Interest expense 0.46M 0.85M 1.11M 0.69M 0.36M
Tax provision -0.29786M -0.01755M 1.69M 0.46M 1.70M
Interest income 2.30M 3.80M 4.28M 0.38M 0.08M
Net interest income 1.84M 2.95M 3.18M -0.31582M -0.28760M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.29786M -0.01755M 1.69M 0.46M 1.70M
Total revenue 7.67M 0.10M 18.11M 9.29M 10.18M
Total operating expenses 29.11M 36.05M 41.83M 93.21M 82.54M
Cost of revenue - 0.93M - - -
Total other income expense net 3.53M 2.51M 6.46M 4.41M 0.89M
Discontinued operations - - - - -
Net income from continuing ops -17.60941M -33.42411M -18.94637M -79.97185M -73.17794M
Net income applicable to common shares - - - - -73.20649M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 78.26M 89.27M 115.73M 152.40M 189.51M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.83M 2.58M 3.29M 4.94M 4.06M
Total liab 42.91M 38.74M 45.17M 69.31M 32.95M
Total stockholder equity 35.35M 50.52M 70.56M 83.09M 156.56M
Deferred long term liab - - - - -
Other current liab 12.75M 15.52M 19.72M 22.54M 16.50M
Common stock 0.00592M 0.00589M 0.00555M 0.00550M 0.00563M
Capital stock 0.00592M 0.00589M 0.00555M 0.00550M 0.00563M
Retained earnings -328.78500M -311.17559M -277.75148M -258.80511M -178.83326M
Other liab - - - 0.03M 0.14M
Good will - - - - -
Other assets - -0.02211M 0.00000M 0.11M 0.07M
Cash 74.52M 85.19M 109.93M 143.76M 174.39M
Cash and equivalents - - - - -
Total current liabilities 25.17M 38.18M 31.46M 55.08M 29.82M
Current deferred revenue 3.46M - 0.05M 15.11M 5.50M
Net debt -68.26056M -66.70096M -87.62739M -115.78745M -166.90187M
Short term debt 5.07M 17.93M 8.59M 13.77M 4.50M
Short long term debt 4.98M 17.79M 8.40M 13.62M 4.50M
Short long term debt total 6.26M 18.49M 22.31M 27.97M 7.49M
Other stockholder equity 366.04M 362.22M 350.11M 342.74M 335.48M
Property plant equipment - - - 2.97M 3.49M
Total current assets 77.38M 87.78M 113.44M 149.32M 185.95M
Long term investments - - - - -
Net tangible assets - - - 83.09M 156.56M
Short term investments - - - - -
Net receivables 0.02M 0.00831M 0.22M 0.62M 7.51M
Long term debt 1.14M 0.42M 13.54M 14.15M 2.99M
Inventory - - - - -
Accounts payable 2.88M 4.24M 3.09M 3.67M 3.32M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.91483M -0.52690M -1.80009M -0.84930M -0.09398M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.03M 0.10M 0.08M 0.11M 0.07M
Deferred long term asset charges - - - - -
Non current assets total 0.89M 1.51M 2.29M 3.08M 3.56M
Capital lease obligations 0.15M 0.28M 0.37M 0.21M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.49M 1.11M -0.07736M -0.68605M -2.50993M
Change to liabilities - - - 0.00000M 6.33M
Total cashflows from investing activities 0.48M 1.11M -0.07736M - -2.50993M
Net borrowings -12.24291M -3.42450M -5.37245M - -0.70286M
Total cash from financing activities 4.45M 3.77M -5.36695M 17.82M 145.36M
Change to operating activities - - - - 4.36M
Net income -17.60941M -33.42411M -18.94637M -79.97185M -73.17794M
Change in cash -10.67072M -24.73975M -33.82442M -30.63256M 99.24M
Begin period cash flow 85.19M 109.93M 143.76M 174.39M 75.15M
End period cash flow 74.52M 85.19M 109.93M 143.76M 174.39M
Total cash from operating activities -15.65745M -29.70098M -28.45484M -48.61169M -43.41462M
Issuance of capital stock 16.55M 7.33M 0.00000M 0.00000M 149.79M
Depreciation 0.59M 0.93M 1.21M 1.45M 1.13M
Other cashflows from investing activities 0.00140M 0.00017M 0.00766M - -
Dividends paid - - - - 4.61M
Change to inventory - - - - 6.02M
Change to account receivables -0.00904M 0.21M 0.40M 3.00M -3.00000M
Sale purchase of stock - 0.00000M 0.00000M -3.97668M -2.36158M
Other cashflows from financing activities 16.55M -0.13730M 0.00550M 26.15M 7.63M
Change to netincome - - - - 19.29M
Capital expenditures 0.02M 0.03M 0.09M 0.69M 2.51M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.77530M -1.89045M -16.55179M 21.94M 9.35M
Stock based compensation 3.74M 4.91M 7.27M 10.52M 18.68M
Other non cash items -1.60408M -0.22224M -1.43684M -2.54851M -0.00995M
Free cash flow -15.67450M -29.73456M -28.53985M -49.30262M -45.92455M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ADAG
Adagene Inc		 0.14 3.65% 3.98 - - 32.73 7.27 24.61 1.12
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Adagene Inc

Building C14, Suzhou, China, 215123

Key Executives

Name Title Year Born
Dr. Peter P. Luo Ph.D. Co-Founder, CEO & Chairman 1966
Mr. Man Kin Tam M.B.A. CFO & Director 1977
Dr. Fangyong Du Ph.D. Chief Technology Officer 1970
Dr. Jc Xu M.D., Ph.D. Chief Scientific Officer 1965
Ms. Ami Celeste Knoefler VP of Investor Relations & Corp. Communications NA
Ms. Ling Zhou Head of HR NA
Dr. Qinghai Zhao Chief Manufacturing Officer 1961
Ms. Yan Li M.B.A. Sr. VP of Bioinformatics & Information Technology 1975
Ms. Xiaohong She Sr. VP & Head of Clinical Operations 1967
Dr. Guizhong Liu Ph.D. Head of Biology & Pharmacology 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.